BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

OnKure Therapeutics updates on PIKture-01 trial progress, financial results, and expansion of PI3Ka programs, with milestones expected through 2026. OnKure Therapeutics provided an update on its ...

With its lead asset RLY-2608, a PI3Ka inhibitor showing promising results in breast cancer trials, and a recent strategic acquisition, Relay is positioning itself as a potential leader in targeted ...

OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

Cash and cash equivalents were approximately $110.8 million as of December 31, 2024. “I am extremely pleased with the progress we made last ...

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; ...

Relay Therapeutics specializes in developing targeted therapies for cancer patients, with a particular emphasis on precision medicines. The company’s flagship product, RLY-2608, is a PI3Ka ...

“I am extremely pleased with the progress we made last year. With three PI3Ka inhibitor programs, including one in clinical development and a second development candidate expected next ...

Relay Therapeutics specializes in developing targeted therapies for cancer patients, with a particular emphasis on precision medicines. The company’s flagship product, RLY-2608, is a PI3Ka inhibitor ...